Mark Genovese: Crohn’s disease is a chronic, inflammatory bowel disease associated with progressive bowel damage, disability, ...
Piper Sandler analyst maintains an Overweight rating on Teva, citing positive feedback on duvakitug's potential in treating ...
Inc. (NYSE American: PTN), a small-cap biotech company with a market capitalization of $20.4 million, has announced its corporate milestones for 2025, focusing on the development of treatments for ...
The FDA granted approval to Eli Lilly and Company’s mirikizumab-mrkz (Omvoh) for Crohn disease, expanding its treatment reach ...
Odyssey Therapeutics is a promising biotech firm poised for IPO success with a focus on inflammatory and autoimmune diseases ...
Many with Crohn’s disease or ulcerative colitis sacrifice essential purchases like food and clothing for healthcare, survey ...
Turmeric's active compound, curcumin, is a potent anti-inflammatory and antioxidant that can help with conditions like ...
The study's primary goal is to assess the therapy’s tolerability, pharmacokinetics and safety in healthy volunteers.
Children who were diagnosed with inflammatory bowel disease (IBD) showed a decline in height, weight, and body mass index ...
The U.S. Food and Drug Administration has approved Eli Lilly's Omvoh (mirikizumab-mrkz) for the treatment of moderately to ...
Omvoh is now approved in the U.S. for two types of inflammatory bowel disease (IBD), following its October 2023 approval as a ...
The FDA has approved Omvoh for the treatment of moderately to severely active Crohn’s disease, making it the second ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback